Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,896.88 +2,152.41 (+3.27%) CMC Crypto 200
1,374.94 +44.33 (+3.33%)
Repare Therapeutics Inc. (RPTX)
After hours:
| Previous close | 3.9000 |
| Open | 3.9300 |
| Bid | 3.9200 x 100 |
| Ask | 4.0100 x 100 |
| Day's range | 3.8950 - 4.0100 |
| 52-week range | 2.9800 - 13.8500 |
| Volume | |
| Avg. volume | 260,736 |
| Market cap | 167.235M |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1000 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.67 |
ZacksTango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CNW GroupAlberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund
Alberta Enterprise Corporation (AEC) announced today that it has invested US$7.5 million into Amplitude Ventures' US$192-million Fund II to give early stage Alberta health and life science startups the continuing opportunity to access Amplitude's specialized precision medicine expertise and investment. Amplitude is also establishing a full-time presence in Alberta with a new hire.
Business WireRepare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
CAMBRIDGE, Mass. & MONTREAL, June 26, 2024--Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
